Incidence of Parenteral Nutrition-Associated Liver Disease in Infants on Prolonged Parenteral Nutrition with a Soybean-Based Lipid Emulsion: A 7-Year Experience

Parenteral nutrition associated liver disease (PNALD) is a significant complication in infants receiving long-term parenteral nutrition (PN). Chronic administration of PN has been associated with its development. Our purpose is to characterize our incidence of PNALD over an extended period and identify risk factors for its development, including administration of soybean-based injectable lipid emulsions (ILEs) as we transit to novel ILEs in our practice. Infants receiving 30 days or more of PN were included. PNALD was defined as a direct bilirubin ≥ 2 mg/dL. Data collected included: patient demographics, clinical and enteral feeding characteristics. Macronutrient intake was recorded using these cut-offs: glucose infusion rate (GIR) of ≤14 mg/kg/min or above, protein doses of ≤3 g/kg/day or above and lipid doses of ≤2 g/kg/day or above. A total of 349 infants were included, with an annual incidence of PNALD ranging between 34% - 54%. Infants with PNALD were younger by gestation (27 vs. 29.5 weeks) and smaller by birthweight (900 vs. 1248 grams). Sepsis, GI disease including necrotizing enterocolitis and bowel resection were significantly associated with an increased risk for development of PNALD. PNALD infants received lower protein doses (3.0 vs 3.3 g/kg/day, p = 0.014) while receiving higher GIR (11.4 vs 10.7 mg/kg/min, p = 0.012) compared to non-PNALD infants. Low birth weight, sepsis and bowel resection remain strong indicators of risk for PNALD. No single macronutrient increased our infants’ risk for PNALD. The use of newer ILEs when available should be evaluated for their impact on PNALD development.

[1]  E. Huang,et al.  Use of a Gastroschisis Feeding Guideline to Improve Standardization of Care and Patient Outcomes at an Urban Children's Hospital , 2018, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[2]  M. Rocchi,et al.  Half-life of plasma phytosterols in very low birth weight preterm infants on routine parenteral nutrition with vegetable oil-based lipid emulsions. , 2016, Clinical nutrition.

[3]  B. Feldman,et al.  Preventing the Progression of Intestinal Failure–Associated Liver Disease in Infants Using a Composite Lipid Emulsion: A Pilot Randomized Controlled Trial of SMOFlipid , 2017, JPEN. Journal of parenteral and enteral nutrition.

[4]  S. Shew,et al.  Low-Dose Parenteral Soybean Oil for the Prevention of Parenteral Nutrition–Associated Liver Disease in Neonates With Gastrointestinal Disorders: A Multicenter Randomized Controlled Pilot Study , 2017, JPEN. Journal of parenteral and enteral nutrition.

[5]  Tamekia Jones,et al.  Standardization of Feeding Advancement After Neonatal Gastrointestinal Surgery: Does It Improve Outcomes? , 2014, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[6]  H. Arnell,et al.  Impact of Parenteral Fat Composition on Cholestasis in Preterm Infants , 2015, Journal of pediatric gastroenterology and nutrition.

[7]  C. Compher,et al.  A.S.P.E.N. clinical guidelines: support of pediatric patients with intestinal failure at risk of parenteral nutrition-associated liver disease. , 2014, JPEN. Journal of parenteral and enteral nutrition.

[8]  E. Huang,et al.  Evaluation of parenteral nutrition-associated liver disease in infants with necrotizing enterocolitis before and after the implementation of feeding guidelines. , 2014, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[9]  C. Compher,et al.  Clinical Guidelines : Support of Pediatric Patients With Intestinal Failure at Risk of Parenteral Nutrition – Associated Liver Disease , 2014 .

[10]  K. Setchell,et al.  Phytosterols Promote Liver Injury and Kupffer Cell Activation in Parenteral Nutrition–Associated Liver Disease , 2013, Science Translational Medicine.

[11]  You-sheng Li,et al.  Pathogenesis and treatment of parenteral nutrition-associated liver disease. , 2012, Hepatobiliary & pancreatic diseases international : HBPD INT.

[12]  S. Chotinaruemol,et al.  Incidence and risk factors of parenteral nutrition‐associated liver disease in newborn infants , 2012, Pediatrics international : official journal of the Japan Pediatric Society.

[13]  D. Teitelbaum,et al.  Intravenous fat emulsions reduction for patients with parenteral nutrition-associated liver disease. , 2012, The Journal of pediatrics.

[14]  E. Huang,et al.  Enteral Fish Oil for Treatment of Parenteral Nutrition‐Associated Liver Disease in Six Infants with Short‐Bowel Syndrome , 2011, Pharmacotherapy.

[15]  L. Kalish,et al.  Risk Factors for Parenteral Nutrition–associated Liver Disease Following Surgical Therapy for Necrotizing Enterocolitis , 2011, Journal of pediatric gastroenterology and nutrition.

[16]  W. D. Jackson,et al.  Elimination of soybean lipid emulsion in parenteral nutrition and supplementation with enteral fish oil improve cholestasis in infants with short bowel syndrome. , 2010, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[17]  S. Abrams,et al.  High rates of mortality and morbidity occur in infants with parenteral nutrition-associated cholestasis. , 2010, JPEN. Journal of parenteral and enteral nutrition.

[18]  San-Nan Yang,et al.  Parenteral nutrition-associated cholestasis in premature babies: risk factors and predictors. , 2009, Pediatrics and neonatology.

[19]  Hau D. Le,et al.  Parenteral Fish Oil Improves Outcomes in Patients With Parenteral Nutrition-Associated Liver Injury , 2009, Annals of surgery.

[20]  J. Koopmeiners,et al.  The association of cyclic parenteral nutrition and decreased incidence of cholestatic liver disease in patients with gastroschisis. , 2009, Journal of pediatric surgery.

[21]  A. Spitzer,et al.  Demographic and nutritional factors associated with prolonged cholestatic jaundice in the premature infant , 2008, Journal of Perinatology.

[22]  R. Ehrenkranz,et al.  Parenteral nutrition-associated cholestasis in small for gestational age infants. , 2008, The Journal of pediatrics.

[23]  M. Park,et al.  Could lipid infusion be a risk for parenteral nutrition-associated cholestasis in low birth weight neonates? , 2008, European Journal of Pediatrics.

[24]  J. Burnett,et al.  Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition-associated liver disease , 2007, Journal of Perinatology.

[25]  P. Tsao,et al.  Ursodeoxycholic acid (UDCA) therapy in very-low-birth-weight infants with parenteral nutrition-associated cholestasis. , 2004, The Journal of pediatrics.

[26]  P. Thureen,et al.  Aggressive nutrition of the very low birthweight infant. , 2002, Clinics in perinatology.

[27]  R. T. Coutts,et al.  Effects of intravenous lipid as a source of energy in parenteral nutrition associated hepatic dysfunction and lidocaine elimination: a study using isolated rat liver perfusion , 1997, Biopharmaceutics & drug disposition.

[28]  D. Teitelbaum,et al.  Treatment of parenteral nutrition-associated cholestasis with cholecystokinin-octapeptide. , 1995, Journal of pediatric surgery.

[29]  S. Kneip,et al.  Direct regulation of bile secretion by prostaglandins in perfused rat liver , 1994, Hepatology.

[30]  A. Coran,et al.  An analysis of factors contributing to the development of total parenteral nutrition-induced cholestasis. , 1989, JPEN. Journal of parenteral and enteral nutrition.

[31]  W. Maniscalco,et al.  Decreased cholestasis with enteral instead of intravenous protein in the very low-birth-weight infant. , 1989, Journal of pediatric gastroenterology and nutrition.